Navigation Links
Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Sept. 28, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018


GlobalData, the industry analysis specialist, has released its new report, "Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report identifies the key trends shaping and driving the global acute ischemic stroke therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acute ischemic stroke therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.


The report provides information on the key drivers and challenges of the acute ischemic stroke market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) acute ischemic stroke therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as immunomodulators, NMDA receptor antagonists, platelet inhibitor, polyketide antibiotics, and recombinant proteins amongst others.

- Analysis of the current and future competition in the seven key countries acute ischemic stroke therapeutics market. Key market players covered are Celgene Corporation, Cidat C.V. Corrimum Gmbh, D-Pharm Ltd., H Lundbeck A/S, Mitsubhishi Tanabe Pharma, Panacea Pharmaceuticals, Pfizer, Inc., Sanofi, Stemedica Cell Technologies, Vernalis PLC.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the acute ischemic stroke market.

- Analysis of key recent licensing and partnership agreements in acute ischemic stroke therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global acute ischemic stroke market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute ischemic stroke market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global acute ischemic stroke market landscape? – Identify, understand and capitalize.

To order this report:

: Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
(Date:10/13/2015)... Fla. , Oct. 13, 2015   Vigilant ... of solutions that aid in the early detection and ... has awarded Vigilant,s founder and CEO, Matthew H.J. ... Year Award, which recognizes an entrepreneur who has made ... life sciences industry in the leadership of ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... 13, 2015   Happy Vitals ®, ... home testing kit for breast milk.  The ... an unparalleled, detailed assessment of the nutrition ... carbs and key vitamins—all charted over time ... health tracking.  In addition, Happy Vitals also offers ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. ... bone, and blood. But how much protein does the average man need in order ... according to the October 2015 issue of Harvard Men's Health Watch . Most ...
(Date:10/13/2015)... Waycross, GA (PRWEB) , ... October 13, 2015 ... ... charitable nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along ... (FTP) announce the collective schedule for their regional telehealth summits for Fall 2015. ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an ESPN report published on ... teammate accidentally elbowed him in the left eye during the first day of practice ... of a series of setbacks, including a knee injury that has interfered with his ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):